ライフサイエンスコーパス: Kaposi's sarcoma

1 Castleman's disease, as well as its namesake Kaposi's sarcoma.

2 elated malignancies, including lymphomas and Kaposi's sarcoma.

3 of vGPCR-induced lesions that resemble human Kaposi's sarcoma.

4 eta3 in KSHV pathogenesis and development of Kaposi's sarcoma.

5 d herpesvirus (KSHV), the etiologic agent of Kaposi's sarcoma.

6 homas, multicentric Castleman's disease, and Kaposi's sarcoma.

7 ovarian, breast, and lung cancer, as well as Kaposi's sarcoma.

8 an's disease, primary effusion lymphoma, and Kaposi's sarcoma.

9 9, 95% CI 1.67-1.72), AIDS-defining cancers (Kaposi's sarcoma [498.11, 477.82-519.03], non-Hodgkin ly

10 mmaherpesvirus etiologically associated with Kaposi's sarcoma, a vascular tumor of endothelial cells.

11 SHV) is the cause of aggressive AIDS-related Kaposi's sarcoma (AIDS-KS) characterized by abnormal ang

12 two B-cell lymphoproliferative diseases and Kaposi's sarcoma, an endothelial-cell-driven cancer.

13 erpesvirus 8 (HHV-8), the causative agent of Kaposi's sarcoma and B cell neoplasms in AIDS patients,

14 herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma and is associated with two B cell malig

15 s tightly associated with the development of Kaposi's sarcoma and multicentric Castleman's disease, a

16 -cell pathologies, including AIDS-associated Kaposi's sarcoma and multicentric Castleman's disease.

17 tients at the Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic infections (GHESKIO)

18 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma and other B-cell cancers and remains a

19 is an oncogenic gammaherpesvirus that causes Kaposi's sarcoma and other lymphoproliferative disorders

20 rpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma and primary effusion lymphoma (PEL).

21 herpesvirus (KSHV), the etiological agent of Kaposi's sarcoma and primary effusion lymphoma, has deve

22 ted herpesvirus (KSHV) is causally linked to Kaposi's sarcoma and several lymphoproliferative disease

23 herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma, and a constitutively active viral G pr

24 IFI16 knockdown disrupted the latency of Kaposi's sarcoma associated herpesvirus (KSHV) and induc

25 Kaposi's sarcoma associated herpesvirus (KSHV) establish

26 ing an m(6)A-modified hairpin present in the Kaposi's sarcoma associated herpesvirus (KSHV) ORF50 RNA

27 Human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma associated herpesvirus (KSHV), is an on

28 G, and panel), Epstein-Barr Virus (EBV), and Kaposi's Sarcoma-associated Herpes Virus (KSHV) in a fin

29 Kaposi's sarcoma-associated herpes virus (KSHV) is the c

30 During the latent phase, Kaposi's sarcoma-associated herpes virus (KSHV) maintain

31 Kaposi's sarcoma-associated herpes virus (KSHV) polyaden

32 r maturation of RRV, the closest relative of Kaposi's sarcoma-associated herpesvirus (KSHV) (a human

33 The Kaposi's sarcoma-associated herpesvirus (KSHV) alkaline

34 ymphomas (PELs) are causally associated with Kaposi's sarcoma-associated herpesvirus (KSHV) and 86% o

35 protein (SCP) of human tumor herpesviruses--Kaposi's sarcoma-associated herpesvirus (KSHV) and Epste

36 Kaposi's sarcoma-associated herpesvirus (KSHV) and Epste

37 Kaposi's sarcoma-associated herpesvirus (KSHV) and Epste

38 s KSHV-miR-K12-11 and MDV-miR-M4, encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) and Marek

39 Two closely related gammaherpesviruses, Kaposi's sarcoma-associated herpesvirus (KSHV) and rhesu

40 Kaposi's sarcoma-associated herpesvirus (KSHV) and the c

41 Both Kaposi's sarcoma-associated herpesvirus (KSHV) and the c

42 ed with the closely related gammaherpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV) and the m

43 Both Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are human

44 DNA tumor viruses such as Kaposi's sarcoma-associated herpesvirus (KSHV) are known

45 The vTAs in Kaposi's sarcoma-associated herpesvirus (KSHV) are ORF18

46 al carcinogens, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are two o

47 Using the dimeric protease (Pr) from Kaposi's sarcoma-associated herpesvirus (KSHV) as a mode

48 Assembly of Kaposi's sarcoma-associated herpesvirus (KSHV) begins at

49 of arachidonic acid pathways of the host in Kaposi's sarcoma-associated herpesvirus (KSHV) biology h

50 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) cause lif

51 ive stages of the KSHV life cycle.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) causes AI

52 Kaposi's sarcoma-associated herpesvirus (KSHV) causes tw

53 Here, we addressed whether the oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) deregulat

54 Detectable Kaposi's sarcoma-associated herpesvirus (KSHV) DNA in bl

55 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes 1

56 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes 1

57 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes m

58 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes t

59 encoded by open reading frame 36 (ORF36) of Kaposi's sarcoma-associated herpesvirus (KSHV) enhances

60 Kaposi's sarcoma-associated herpesvirus (KSHV) enters hu

61 Kaposi's sarcoma-associated herpesvirus (KSHV) evades ho

62 The human oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) expresses

63 Moreover, a recombinant Kaposi's sarcoma-associated herpesvirus (KSHV) expressin

64 inity tagged and purified all 89 proteins of Kaposi's sarcoma-associated herpesvirus (KSHV) from huma

65 Lytic activation of Kaposi's sarcoma-associated herpesvirus (KSHV) from late

66 Reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) from late

67 ous transcription across the entirety of the Kaposi's sarcoma-associated herpesvirus (KSHV) genome an

68 e found that most transcripts encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV) genome un

69 Latent Kaposi's sarcoma-associated herpesvirus (KSHV) genomes e

70 y focal assembly of RNA polymerase II around Kaposi's sarcoma-associated herpesvirus (KSHV) genomes i

71 ected cells.IMPORTANCE B cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) harbor mu

72 Kaposi's sarcoma-associated herpesvirus (KSHV) has a cau

73 Kaposi's sarcoma-associated herpesvirus (KSHV) has been

74 Kaposi's sarcoma-associated herpesvirus (KSHV) has laten

75 Oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) has laten

76 Kaposi's sarcoma-associated herpesvirus (KSHV) has tropi

77 we present an innovative approach to culture Kaposi's sarcoma-associated herpesvirus (KSHV) infected

78 d levels of viral lytic gene expression when Kaposi's sarcoma-associated herpesvirus (KSHV) infected

79 L) is a lymphogenic disorder associated with Kaposi's sarcoma-associated herpesvirus (KSHV) infection

80 Kaposi's sarcoma-associated herpesvirus (KSHV) infection

81 Kaposi's sarcoma-associated herpesvirus (KSHV) infection

82 was undertaken to determine whether de novo Kaposi's sarcoma-associated herpesvirus (KSHV) infection

83 an effective small-animal model to study the Kaposi's sarcoma-associated herpesvirus (KSHV) infection

84 script C19ORF66 and showed that it restricts Kaposi's sarcoma-associated herpesvirus (KSHV) infection

85 Kaposi's sarcoma-associated herpesvirus (KSHV) infects m

86 Latent DNA replication of Kaposi's sarcoma-associated herpesvirus (KSHV) initiates

87 The K15P membrane protein of Kaposi's sarcoma-associated herpesvirus (KSHV) interacts

88 Kaposi's sarcoma-associated herpesvirus (KSHV) interacts

89 Kaposi's sarcoma-associated herpesvirus (KSHV) is a DNA

90 Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

91 Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

92 The ORF45 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

93 Kaposi's sarcoma (KS) caused by oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) is a high

94 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

95 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

96 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

97 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

98 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

99 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

100 inhibiting viral gene expression.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is a path

101 Kaposi's sarcoma-associated herpesvirus (KSHV) is a prom

102 ting their premature accumulation.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is an onc

103 Kaposi's sarcoma-associated herpesvirus (KSHV) is an onc

104 predominantly canonical in nature.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is associ

105 g the intracellular redox balance.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is associ

106 l that enhance antiviral defenses.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is causal

107 Kaposi's sarcoma-associated herpesvirus (KSHV) is causat

108 The K1 gene product of Kaposi's sarcoma-associated herpesvirus (KSHV) is encode

109 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

110 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

111 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

112 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

113 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

114 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

115 d transmission in the oral cavity.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

116 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

117 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

118 Co-infection with HIV-1 and Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

119 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

120 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

121 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

122 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

123 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

124 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

125 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

126 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

127 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

128 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

129 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

130 The DNA virus Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

131 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

132 on of the STAT3 signaling pathway.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

133 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

134 ects in KSHV late gene expression.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

135 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

136 lytic phases.IMPORTANCE The K15P protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is though

137 Lytic activation of the cancer-causing Kaposi's sarcoma-associated herpesvirus (KSHV) is vital

138 The Kaposi's sarcoma-associated herpesvirus (KSHV) LANA prot

139 Kaposi's sarcoma-associated herpesvirus (KSHV) latency-a

140 on factors which play important roles in the Kaposi's sarcoma-associated herpesvirus (KSHV) latent an

141 Specific regions of Kaposi's sarcoma-associated herpesvirus (KSHV) latent ep

142 e factors (HIFs) play important roles in the Kaposi's sarcoma-associated herpesvirus (KSHV) life cycl

143 r, Ago2 and DCP1A, in PB formation, and that Kaposi's sarcoma-associated herpesvirus (KSHV) lytic inf

144 at the constitutive AMPK activity restricted Kaposi's sarcoma-associated herpesvirus (KSHV) lytic rep

145 veloping germinal center B cells, can induce Kaposi's sarcoma-associated herpesvirus (KSHV) lytic rep

146 Kaposi's sarcoma-associated herpesvirus (KSHV) maintains

147 tic targets to control KS lesions.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) manipulat

148 Sequence comparisons to human Kaposi's sarcoma-associated herpesvirus (KSHV) miRNAs re

149 DSBs) in DNA, although detail concerning how Kaposi's sarcoma-associated herpesvirus (KSHV) modulates

150 egy of selectively isolating VLVs by using a Kaposi's sarcoma-associated herpesvirus (KSHV) mutant th

151 The Kaposi's sarcoma-associated herpesvirus (KSHV) open read

152 ere, we identify a viral trimeric complex of Kaposi's sarcoma-associated herpesvirus (KSHV) open read

153 Although Kaposi's sarcoma-associated herpesvirus (KSHV) ORF52 (al

154 We report here that Kaposi's sarcoma-associated herpesvirus (KSHV) ORF52, an

155 The Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 gen

156 Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 pla

157 Kaposi's sarcoma-associated herpesvirus (KSHV) ORF6 is h

158 ncy-associated nuclear antigen (LANA) of the Kaposi's sarcoma-associated herpesvirus (KSHV) performs

159 Molecular mechanisms of Kaposi's sarcoma-associated herpesvirus (KSHV) reactivat

160 The lytic replication of Kaposi's sarcoma-associated herpesvirus (KSHV) requires

161 nprecedented mechanism of viral replication: Kaposi's sarcoma-associated herpesvirus (KSHV) stably cl

162 recently showed that the interaction between Kaposi's sarcoma-associated herpesvirus (KSHV) tegument

163 e kinase A2 (EphA2) is an entry receptor for Kaposi's sarcoma-associated herpesvirus (KSHV) that is e

164 sociated substrate) as a platform to promote Kaposi's sarcoma-associated herpesvirus (KSHV) trafficki

165 Kaposi's sarcoma-associated herpesvirus (KSHV) transcrib

166 Kaposi's sarcoma-associated herpesvirus (KSHV) transcrip

167 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) utilize c

168 We assessed whether elevated Kaposi's sarcoma-associated herpesvirus (KSHV) viral loa

169 rophoretic response of B cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) were inve

170 e expression occurs upon superinfection with Kaposi's sarcoma-associated herpesvirus (KSHV), a common

171 Kaposi's sarcoma-associated herpesvirus (KSHV), a DNA tu

172 We report that ORF10 of Kaposi's sarcoma-associated herpesvirus (KSHV), a nuclea

173 iral FLICE-like inhibitor protein (vFLIP) of Kaposi's sarcoma-associated herpesvirus (KSHV), against

174 Kaposi's sarcoma-associated herpesvirus (KSHV), also kno

175 ncy is an integral part of the life cycle of Kaposi's sarcoma-associated herpesvirus (KSHV), an etiol

176 V1) lineage consists of human herpesvirus 8, Kaposi's sarcoma-associated herpesvirus (KSHV), and clos

177 DNA tumor viruses Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV), and huma

178 osely related to human herpesvirus 8 (HHV-8)/Kaposi's Sarcoma-associated herpesvirus (KSHV), and it i

179 luding human Epstein-Barr virus (EBV), human Kaposi's sarcoma-associated herpesvirus (KSHV), and muri

180 lular reservoir in individuals infected with Kaposi's sarcoma-associated herpesvirus (KSHV), and the

181 iruses, including the human gammaherpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), and the

182 the replication of the oncogenic herpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), by targe

183 aherpesviruses, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), can caus

184 , an immediate-early and tegument protein of Kaposi's sarcoma-associated herpesvirus (KSHV), causes s

185 n adaptive immunity, many viruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), have evo

186 The human gammaherpesvirus, Kaposi's sarcoma-associated herpesvirus (KSHV), is tight

187 by viral endoribonucleases, including SOX in Kaposi's sarcoma-associated herpesvirus (KSHV), muSOX in

188 egument proteins of herpesviruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), play key

189 Kaposi's sarcoma-associated herpesvirus (KSHV), the caus

190 infection and KS.IMPORTANCE The ability for Kaposi's sarcoma-associated herpesvirus (KSHV), the caus

191 rld primates and are distinct but related to Kaposi's sarcoma-associated herpesvirus (KSHV), the etio

192 Kaposi's sarcoma-associated herpesvirus (KSHV), the etio

193 on lymphoma (PEL) cells infected with latent Kaposi's sarcoma-associated herpesvirus (KSHV), the prom

194 In Kaposi's sarcoma-associated herpesvirus (KSHV), these vT

195 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), which ar

196 Here, we show that the Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded L

197 The Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded l

198 Kaposi's sarcoma-associated herpesvirus (KSHV)-induced a

199 n by HIV-1 promotes the aggressive growth of Kaposi's sarcoma-associated herpesvirus (KSHV)-related m

200 Kaposi's sarcoma-associated herpesvirus (KSHV)-related m

201 Kaposi's sarcoma-associated herpesvirus (KSHV)-transform

202 shown that, unlike glucose-addicted cancers, Kaposi's sarcoma-associated herpesvirus (KSHV)-transform

203 ies.IMPORTANCE We have previously shown that Kaposi's sarcoma-associated herpesvirus (KSHV)-transform

204 nown inflammation related diseases caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

205 for lifelong persistence and pathogenesis of Kaposi's sarcoma-associated herpesvirus (KSHV).

206 erous proliferation of B cells, is caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

207 vo infection of primary endothelial cells by Kaposi's sarcoma-associated herpesvirus (KSHV).

208 EL), which is a viral lymphoma infected with Kaposi's sarcoma-associated herpesvirus (KSHV).

209 Kaposi's sarcoma-associated herpesvirus (KSHV; also call

210 The responsible agent, Kaposi's sarcoma-associated herpesvirus (KSHV; HHV8), ex

211 to recognize late gene promoters.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV; human her

212 16) recognizes nuclear episomal herpesvirus (Kaposi's sarcoma-associated herpesvirus [KSHV], Epstein-

213 Similarly, Kaposi's sarcoma-associated herpesvirus also did not sti

214 ich tumor cells are consistently infected by Kaposi's sarcoma-associated herpesvirus and usually grow

215 c mechanisms by which Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus cause B-cell lym

216 tors (e.g., herpes simplex virus nectin1 and Kaposi's sarcoma-associated herpesvirus EphA2), or assoc

217 IL-4 also reactivated human Kaposi's sarcoma-associated herpesvirus from latency in

218 The Kaposi's sarcoma-associated herpesvirus homologue, ORF61

219 Kaposi's sarcoma-associated herpesvirus is a leading cau

220 Kaposi's sarcoma-associated herpesvirus is the causative

221 s, the cofactor activity (CFA), by using the Kaposi's sarcoma-associated herpesvirus RCA homolog Kapo

222 t HIV, together with a transient increase in Kaposi's sarcoma-associated herpesvirus viral load at we

223 ciated polyomavirus, Epstein-Barr virus, and Kaposi's sarcoma-associated herpesvirus, because GEMs ha

224 ovirus (HCMV), Epstein-Barr virus (EBV), and Kaposi's sarcoma-associated herpesvirus, establish laten

225 genomes, those of human cytomegalovirus and Kaposi's sarcoma-associated herpesvirus, revealing trans

226 nflammatory activities observed in MCD-like "Kaposi's sarcoma-associated herpesvirus-induced cytokine

227 EL clinical samples, and three extracavitary Kaposi's sarcoma-associated herpesvirus-positive solid l

228 ted with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus.

229 rcoma (KS) is a multicentric tumor caused by Kaposi's sarcoma-associated herpesvirus.

230 the organization of this protein complex for Kaposi's sarcoma-associated herpesvirus.

231 nfected with either human cytomegalovirus or Kaposi's sarcoma-associated herpesvirus.

232 f the human pathogens Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus.

233 he gammaherpesviruses Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus.

234 ing TRIM43, that control the reactivation of Kaposi's sarcoma-associated herpesvirus.

235 omolog, the oncogenic human gammaherpesvirus Kaposi's sarcoma-associated herpesvirus/human herpesviru

236 ed for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesviru

237 In 21 cutaneous and/or visceral Kaposi's sarcoma cases, occurring in patients living wit

238 This study defines the mechanism by which Kaposi's sarcoma could be maintained by virus constantly

239 Conjunctival Kaposi's sarcoma developed in 1 patient.

240 d herpesvirus (KSHV), the causative agent of Kaposi's sarcoma, encodes 25 mature viral miRNAs.

241 rt to block the interaction between vFLIP, a Kaposi's sarcoma herpesviral oncoprotein, and NEMO using

242 In lymphomas the Epstein-Barr virus (EBV), Kaposi's sarcoma herpesvirus (KSHV) and human T-lymphotr

243 ressed from the Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV) human DNA tumor viru

244 mutant with prototype foamy virus (PFV) and Kaposi's sarcoma herpesvirus (KSHV) tethering sequences

245 fied infections by Epstein-Barr virus (EBV), Kaposi's sarcoma herpesvirus (KSHV), and human T-lymphot

246 Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV), formally designated

247 an T cell lymphotropic virus-1 (HTLV-1), and Kaposi's sarcoma herpesvirus (KSHV).

248 ow that HHV-8, a DNA tumor virus that causes Kaposi's sarcoma, infects three types of dendritic cells

249 Kaposi's sarcoma is a highly angiogenic tumor that arise

250 Kaposi's sarcoma is a highly vascular tumor, which prefe

251 Kaposi's sarcoma is a highly vascularized, endothelial c

252 Kaposi's sarcoma is one of the most common malignancies

253 Therefore, an understanding of the burden of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) rel

254 KSHV is the causative agent of Kaposi's sarcoma (KS) and other AIDS-related malignancie

255 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

256 virus (KSHV)-related malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

257 Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

258 several AIDS-related malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

259 ked to several human malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

260 Kaposi's sarcoma (KS) as the most common AIDS-associated

261 Kaposi's sarcoma (KS) caused by oncogenic Kaposi's sarco

262 is etiologically associated with endothelial Kaposi's sarcoma (KS) in immunocompromised individuals.

263 Kaposi's sarcoma (KS) is a disease of multifocal vascula

264 Purpose Kaposi's sarcoma (KS) is a multicentric tumor caused by

265 Kaposi's sarcoma (KS) is a rare vascular tumor associate

266 Kaposi's sarcoma (KS) is an AIDS-defining cancer with ab

267 Kaposi's sarcoma (KS) is common in Africa, but economic

268 High prevalence of Kaposi's sarcoma (KS) is seen in diabetic patients.

269 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS), a vascular tumor frequently found

270 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS), an AIDS-defining cancer in HIV-1-

271 herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma (KS), an AIDS-defining cancer with abno

272 of care for patients with HIV diagnosed with Kaposi's sarcoma (KS), but the current role of systemic

273 irus (KSHV) is etiologically associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL),

274 d herpesvirus (KSHV) is the causal agent for Kaposi's sarcoma (KS), the most common malignancy in HIV

275 d herpesvirus (KSHV) is the causal agent for Kaposi's sarcoma (KS), the most common malignancy in peo

276 d herpesvirus (KSHV), the causative agent of Kaposi's sarcoma (KS), to establish and maintain latency

277 ssociated herpesvirus (KSHV) is the cause of Kaposi's sarcoma (KS), which is the most common AIDS-ass

278 Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) infe

279 Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is a

280 Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is t

281 s to block KSHV virion production.IMPORTANCE Kaposi's sarcoma (KS)-associated herpesvirus is the caus

282 (KSHV), is an oncogenic virus that can cause Kaposi's sarcoma (KS).

283 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS).

284 of immunocompromised individuals, including Kaposi's sarcoma (KS).

285 ncluding primary effusion lymphoma (PEL) and Kaposi's sarcoma (KS).

286 pesvirus (KSHV) is the etiological agent for Kaposi's sarcoma (KS).

287 tential risk factors for development of oral Kaposi's sarcoma (KS).

288 s associated with several cancers, including Kaposi's sarcoma (KS).

289 e infected with human herpesvirus 8 (HHV-8) (Kaposi's sarcoma [KS]-associated herpesvirus) and have a

290 ual men were over-represented among men with Kaposi's sarcoma (OR, 48.2; 95% CI, 22.0 to 105.6), anal

291 that are characteristic of HHV-8-associated Kaposi's sarcoma, PEL and multicentric Castleman's disea

292 nd angiogenic activities to HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and m

293 ting it as a contributor to virus-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and m

294 giogenic viral proteins, in HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and m

295 lated diagnoses, oesophageal candidiasis and Kaposi's sarcoma, rose from almost zero to very high lev

296 atently infected TIVE-LTC and PEL cells, and Kaposi's sarcoma skin lesion cells.

297 rs.IMPORTANCE KSHV is the etiologic agent of Kaposi's sarcoma, the most common tumor of AIDS patients

298 al role in the initiation and progression of Kaposi's sarcoma tumors.

299 decreased significantly across 1996-2012 for Kaposi's sarcoma, two subtypes of non-Hodgkin lymphoma,

300 s etiologically associated with all forms of Kaposi's sarcoma worldwide.